Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | NOX2: a potential immune checkpoint for inhibition in AML

Anna Martner • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Checkpoint inhibitors

Myeloid cell NADPH oxidase isoform 2 (NOX2) generates ROS, and recent research indicates that it is a targetable immune checkpoint in cancer. Here, Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses her group’s recent research into NOX2 inhibitors in KRAS-induced murine models of myeloproliferative disease.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Anna Martner

Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
1:50
Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
Anna Martner • 25 Feb 2019
What are the advantages of using histamine dihydrochloride together with immunotherapy?
1:50
What are the advantages of using histamine dihydrochloride together with immunotherapy?
Anna Martner • 24 Feb 2017
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
6:18
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Anna Martner • 24 Feb 2017

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals